Download poster - Target Conference 2014

Glucose imaging in parkinsonisms
S.K. Meles1, L.K. Teune1, A. Tsyganov4, R. Renken2, J. Roerdink3, K.L.Leenders1
1Department of Neurology, University Medical Center Groningen, The Netherlands, 2NeuroImaging
Center Groningen, 3Johann Bernouilli institute of computer science and mathematics , 4TARGET
AIM
Reliable and objective diagnosis of parkinsonian disorders on
the basis of cerebral glucose imaging (FDG-PET) by applying a
multivariate, data-driven technique.
Disease Related
Patterns
PD
METHODS
We studied FDG PET brain data of patients who underwent FDG PET
scanning in the context of their clinical workup. Data were analyzed
using scaled subprofile model and principal component analysis (SSM
PCA). Disease-specific patterns were identified in patients with PD,
MSA and PSP. A disease-related pattern can be prospectively applied
to the FDG PET data of new patients. For each patient a score on
each pattern can be calculated denoting the extent of its expression in
that patient.
New Patient
MSA
RESULTS
PSP
A multicenter and international website data entry database was
developed recently (www.glimpsproject.com) and contains at present
more than 200 FDG PET scans. Only on the basis of glucose
consumption the multivariate methods (blind for the classes) were able
to differentiate in over 90% of selected cases the conditions PD, MSA
and PSP.
z-score per pattern for individual patient
CONCLUSION
Glucose metabolism with the application of multivariate analysis techniques can be used as an objective screening tool to achieve high accuracy in
diagnosing parkinsonian and dementing disorders in routine clinical practice. In addition, it may be used to identify ideal candidates in clinical trials.
Contact: [email protected]; [email protected]